Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention

Blood Reviews

Volumn 27, Issue 6, 2013, Pages 261-267

  Zhou, Fuling ^a,b   Meng, Shan ^a   Song, Huanjin ^a   Claret, François X ^b,c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Antibody; DKK1; Myeloma bone disease; Proteasome inhibitor; Vaccine

Indexed keywords

BETA CATENIN; BHQ 880; BORTEZOMIB; DICKKOPF 1 DNA VACCINE; DICKKOPF 1 NEUTRALIZING ANTIBODY; DICKKOPF 1 PROTEIN; DNA VACCINE; ENDOTHELIN 1; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE DISEASE; BONE REMODELING; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPROPHYLAXIS; MESENCHYMAL STEM CELL; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELOMA; MYELOMA BONE DISEASE; NONHUMAN; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ANTIBODY; DKK1; MYELOMA BONE DISEASE; PROTEASOME INHIBITOR; VACCINE;

ANIMALS; BONE DISEASES; CELL DIFFERENTIATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION;

EID: 84887606571     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.08.002     Document Type: Article

References (60)

1. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
2. Robbiani D.F., Chesi M., Bergsagel P.L. Bone lesions in molecular subtypes of multiple myeloma. N Engl J Med 2004, 351:197-198.
3. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006, 25:7469-7481.
4. Heider U., Kaiser M., Mieth M., Lamottke B., Rademacher J., Jakob C., et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009, 82:31-38.
5. Qian J., Zheng Y., Zheng C., Wang L., Qin H., Hong S., et al. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 2012, 119:161-169.
6. Klaus A., Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008, 8:387-398.
7. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
8. Oshima T., Abe M., Asano J., Hara T., Kitazoe K., Sekimoto E., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005, 106:3160-3165.
9. Edwards C.M., Edwards J.R., Lwin S.T., Esparza J., Oyajobi B.O., McCluskey B., et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008, 111:2833-2842.
10. Cianferotti L., Demay M.B. VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells. J Cell Biochem 2007, 101:80-88.
11. Fedi P., Bafico A., Nieto Soria A., Burgess W.H., Miki T., Bottaro D.P., et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 1999, 274:19465-19472.
12. Glinka A., Wu W., Delius H., Monaghan A.P., Blumenstock C., Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391:357-362.
13. Mukhopadhyay M., Shtrom S., Rodriguez-Esteban C., Chen L., Tsukui T., Gomer L., et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 2001, 1:423-434.
14. Foley A.C., Mercola M. Heart induction by Wnt antagonists depends on the homeodomain transcription factor Hex. Genes Dev 2005, 19:387-396.
15. MacDonald B.T., Joiner D.M., Oyserman S.M., Sharma P., Goldstein S.A., He X., et al. Bone mass is inversely proportional to Dkk1 levels in mice. Bone 2007, 41:331-339.
16. Estrada K., Styrkarsdottir U., Evangelou E., Hsu Y.H., Duncan E.L., Ntzani E.E., et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012, 44:491-501.
17. Buckland J. Rheumatoid arthritis: genetic variants in DKK1 linked to severity of joint damage in RA. Nat Rev Rheumatol 2012, 8:694.
18. Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A., et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001, 411:321-325.
19. Cheng Z., Biechele T., Wei Z., Morrone S., Moon R.T., Wang L., et al. Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat Struct Mol Biol 2011, 18:1204-1210.
20. Mao B., Wu W., Davidson G., Marhold J., Li M., Mechler B.M., et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002, 417:664-667.
21. Cselenyi C.S., Lee E. Context-dependent activation or inhibition of Wnt-beta-catenin signaling by Kremen. Sci Signal 2008, 1:pe10.
22. Kaiser M., Mieth M., Liebisch P., Oberlander R., Rademacher J., Jakob C., et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008, 80:490-494.
23. Pinzone J.J., Hall B.M., Thudi N.K., Vonau M., Qiang Y.W., Rosol T.J., et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113:517-525.
24. Silvestris F., Lombardi L., De Matteo M., Bruno A., Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leuk Res 2007, 31:129-138.
25. Gregory C.A., Singh H., Perry A.S., Prockop D.J. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 2003, 278:28067-28078.
26. Gunn W.G., Conley A., Deininger L., Olson S.D., Prockop D.J., Gregory C.A. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006, 24:986-991.
27. Corre J., Mahtouk K., Attal M., Gadelorge M., Huynh A., Fleury-Cappellesso S., et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007, 21:1079-1088.
28. Garderet L., Mazurier C., Chapel A., Ernou I., Boutin L., Holy X., et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 2007, 48:2032-2041.
29. Li J., Sarosi I., Cattley R.C., Pretorius J., Asuncion F., Grisanti M., et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006, 39:754-766.
30. Qiang Y.W., Chen Y., Stephens O., Brown N., Chen B., Epstein J., et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112:196-207.
31. Giuliani N., Bataille R., Mancini C., Lazzaretti M., Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98:3527-3533.
32. Gunn W.G., Krause U., Lee N., Gregory C.A. Pharmaceutical inhibition of glycogen synthetase kinase-3beta reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood 2011, 117:1641-1651.
33. Gregory C.A., Gunn W.G., Reyes E., Smolarz A.J., Munoz J., Spees J.L., et al. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann N Y Acad Sci 2005, 1049:97-106.
34. Morvan F., Boulukos K., Clement-Lacroix P., Roman Roman S., Suc-Royer I., Vayssiere B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006, 21:934-945.
35. van der Horst G., van der Werf S.M., Farih-Sips H., van Bezooijen R.L., Lowik C.W., Karperien M. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. J Bone Miner Res 2005, 20:1867-1877.
36. Fujita K., Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007, 6:71.
37. Fowler J.A., Mundy G.R., Lwin S.T., Edwards C.M. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res 2012, 72:2183-2189.
38. Roodman G.D. New potential targets for treating myeloma bone disease. Clin Cancer Res 2006, 12:6270s-6273s.
39. Qiang Y.W., Barlogie B., Rudikoff S., Shaughnessy J.D. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008, 42:669-680.
40. Gavriatopoulou M., Dimopoulos M.A., Christoulas D., Migkou M., Iakovaki M., Gkotzamanidou M., et al. Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 2009, 13:839-848.
41. Terpos E., Heath D.J., Rahemtulla A., Zervas K., Chantry A., Anagnostopoulos A., et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006, 135:688-692.
42. Giuliani N., Morandi F., Tagliaferri S., Lazzaretti M., Donofrio G., Bonomini S., et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007, 67:7665-7674.
43. Politou M.C., Heath D.J., Rahemtulla A., Szydlo R., Anagnostopoulos A., Dimopoulos M.A., et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006, 119:1728-1731.
44. Haaber J., Abildgaard N., Knudsen L.M., Dahl I.M., Lodahl M., Thomassen M., et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 2008, 140:25-35.
45. Durie B.G., Van Ness B., Ramos C., Stephens O., Haznadar M., Hoering A., et al. Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma. Leukemia 2009, 23:1913-1919.
46. Wu P., Walker B.A., Brewer D., Gregory W.M., Ashcroft J., Ross F.M., et al. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin Cancer Res 2011, 17:6347-6355.
47. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.
48. Fulciniti M., Tassone P., Hideshima T., Vallet S., Nanjappa P., Ettenberg S.A., et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114:371-379.
49. Heath D.J., Chantry A.D., Buckle C.H., Coulton L., Shaughnessy J.D., Evans H.R., et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009, 24:425-436.
50. Pozzi S., Fulciniti M., Yan H., Vallet S., Eda H., Patel K., et al. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone 2013, 53:487-496.
51. Zhao J., Kim K.A., Abo A. Tipping the balance: modulating the Wnt pathway for tissue repair. Trends Biotechnol 2009, 27:131-136.
52. Qiang Y.W., Heuck C.J., Shaughnessy J.D., Barlogie B., Epstein J. Proteasome inhibitors and bone disease. Semin Hematol 2012, 49:243-248.
53. Qiang Y.W., Hu B., Chen Y., Zhong Y., Shi B., Barlogie B., et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009, 113:4319-4330.
54. Oyajobi B.O., Garrett I.R., Gupta A., Flores A., Esparza J., Munoz S., et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007, 139:434-438.
55. Patriarca F., Prosdocimo S., Tomadini V., Vasciaveo A., Bruno B., Fanin R. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005, 90:278-279.
56. Zhou F.L., Meng S., Zhang W.G., Wei Y.C., Cao X.M., Bai G.G., et al. Peptide-based immunotherapy for multiple myeloma: current approaches. Vaccine 2010, 28:5939-5946.
57. Qian J., Xie J., Hong S., Yang J., Zhang L., Han X., et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 2007, 110:1587-1594.
58. Levin E.R. Endothelins. N Engl J Med 1995, 333:356-363.
59. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
60. Clines G.A., Mohammad K.S., Bao Y., Stephens O.W., Suva L.J., Shaughnessy J.D., et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007, 21:486-498.